Tumor Type

Liver Cancer - Hepatocellular carcinoma (Secondary to alcohol and adiposity)
Project Profile
Funding Organizations
Research Organizations
Research Activities
Publication Policy

1:   ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML 
2:   Template Letters to Facilitate Communications HTML 
to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors
Clinic & Pathology

France: Assistance Publique - Hôpitaux de Paris (AP-HP)
Centre de Ressource National Biologique des Tumeurs Hépatiques
CHU de Bordeaux
Institut National du Cancer (INCa)

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and it is the third most common cause of cancer mortality. Different risk factors that promote the development of chronic hepatitis, cirrhosis and then HCC include viral etiologies through hepatitis B (HBV) or C (HCV) infection or exposure to Aflatoxin B1 (AFB1); alcohol intake and metabolic syndrome are also major risk factors, alone or in combination with viral infections, particularly in France. Recent comprehensive analysis of large number of genetic and epigenetic alterations together with transcriptome and systematic pathway analyses enabled to identify the HCC diversity, description that is essential toward the definition of a molecular classification. However, the identification of efficient tools for early detection of HCC and innovative targeted-drugs is a major issue that needs the development of new accurate biomarkers.

Eight liver centres in France have joined their effort to collect, preserve and distribute tissue samples from hepatocellular carcinomas, according to the recommendations for Biological Resources Centres (BRC) released by the Organisation for Economic Cooperation and Development (OECD), which were recently implemented in France. This led to the creation of a Liver cancer biobanks network which is recognized by the Ministry of research and the Ministry of health and sponsored by the main research agencies, namely Inserm and INCa. Samples are collected and stored locally, whereas related annotations are remotely collected within a central database. The management of the network includes a Scientific Committee, an Executive Board and an Epidemiology and Management Coordinating Centre. http://chc.isped.u-bordeaux2.fr/

Sequencing & Analysis

France: Centre National de Génotypage (CNG)
Institut National de la Santé et de la Recherche Médicale (INSERM)

Whole genome sequencing (Illumina).

Complementary Studies

France: Fondation Synergie Lyon Cancer
Institut National de la Santé et de la Recherche Médicale (INSERM)

Genomic analyses including SNP-CGH, Transcriptome analyses and miRNA profilling.

Data Storage, Analysis & Management

France: Centre National de Génotypage (CNG)
Project Summary

The aim of the project is to identify a catalog of somatic gene mutations and rearrangements in HCC related to alcohol and metabolic syndrome. As a first step, we will perform a pilot study with a whole genome sequencing of 14 HCC and their corresponding non-tumor liver samples. The mutated genes will be further validated in a series of 500 HCC from the Centre de Ressource National Biologique des tumeurs hépatiques.

Principal Investigators

• Jessica Zucman-Rossi

Lead Jurisdiction